New Estrogen Treatment Brings Hope of Hormonal Balance to Postmenopausal Women

New Estrogen Treatment Brings Hope of Hormonal Balance to Postmenopausal Women

Already a Member? Log In to Your Account

New Estrogen Treatment Brings Hope of Hormonal Balance to Postmenopausal Women

New Estrogen Treatment Brings Hope of Hormonal Balance to Postmenopausal Women

Researchers at Wake Forest Baptist Medical Center have devised a new technique using hormone therapy promising hormonal balance benefits to millions of postmenopausal women worldwide. This systematic procedure is reputed to be effective in treating menopause and osteoporosis in postmenopausal women without the debilitating side effects associated with hormone replacement therapy (HRT). 

 

Most conventional forms of HRT provide symptomatic relief of symptoms associated with menopause, atherosclerosis and osteoporosis, but have also been known to increase the risk of developing uterine cancer, breast cancer, and blood clots which may lead to strokes. For many these findings do not encourage the use of HRT, since the risk-benefit ratio is less than ideal. Selective-estrogen receptor modulators (SERMs) provide both benefits and adverse effects, but the ideal treatment for providing treatment with minimal risk has thus far, proven elusive, according to one of the study authors.

 

The medical research team of Wake Forest Baptist Medical Center collaborating with pharmaceutical corporation Pfizer has concluded testing a new strategy they call Tissue Selective Estrogen Combination (TSEC). Using this strategy conventional estrogen was combined with a bone-protective SERM-like drug called bazedoxifene acetate, to create a complimentary combination of tissue effects that maximize the benefits of HRT while avoiding its risk factors.

 

The study comprised of a 20-month randomized study which also included some post-menopausal non-human primates were involved in testing the effect of TSEC on the breast, uterus, and cardiovascular system.

 

The TSEC strategy was used in the selective estrogen, menopause, and response therapy (SMART) phase 3 trials involving more than 6,000 women. However, the study authors note that primate trials are an important part of the study because it allows the researchers to address tissue responses directly, whereas studies involving human female test subjects may take years to provide adequate clinical results, thus prolonging gathering conclusive results.


This study was published in the journal Menopause, a key publication of the North American Menopause Society. TSEC strategy may allow postmenopausal women to experience the benefits of HRT while avoiding the harmful side-effects, such as, breast and uterine cancer. This remarkable finding may encourage more new approaches to treating problems for women with menopause and osteoporosis but further research is needed.

 

Osteoporosis was treated with HRT's much earlier than most other medical treatments, however, due to the Women's Health Initiative, the reports of the dangers of HRT has prompted people to seek other treatments like bisphosphonates. New approaches to HRT may some day be used in terms of medical treatment -- one which avoids complications of side-effects, such as, those cases involving the class action litigations resulting from Fosamax femur fractures. For more updates visit www.fosamaxclassaction.us/femur-fractures today.

 

  Article Info
Created: Dec 21 2012 at 11:09:43 AM
Updated: Dec 21 2012 at 11:15:02 AM
Category: Health
Language: English

  Share
Stumbleupon
Digg
Delicious
Reddit
© 2006-2014 OnToplist.com, All Rights Reserved